Arcinova Names Christian Dowdeswell Managing Director

Arcinova, a Quotient Sciences company, and UK-based CRDMO, appointed Dr. Christian Dowdeswell as the new Managing Director.

Dowdeswell succeeds co-founder and Managing Director, Paul Ryan, who recently announced his retirement. Dowdeswell joins the firm after its recent relaunch with a refreshed brand identity and a renewed focus on delivering integrated drug substance and early drug product services to global biotech and pharmaceutical partners.

Bringing over 25 years of sector experience to his role, Dowdeswell joins Arcinova from consulting and advisory positions with companies including Nanoform and Pangaea Life Sciences. 

Previously, he served as Chief Business Officer for Drug Substances at global life sciences company Siegfried AG, and held various senior positions at Lonza, most recently as Vice President and Global Head of Commercial Development for Lonza’s small molecules custom manufacturing business.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, commented: “He brings a wealth of experience and knowledge of the global CDMO market to the role. Christian’s leadership will be instrumental as Arcinova continues to grow and deliver client service excellence, as we help our customers accelerate the development of new medicines.”